Jochen Maurer

Dr. Jochen Maurer

University Hospital RWTH Aachen, Aachen, North Rhine-Westphalia, Germany
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2015 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
BPBogdan‐Tiberius Preca
Bogdan‐Tiberius Preca
Karolina Bajdak-RusinekKarolina Bajdak-Rusinek
Karolina Bajdak-Rusinek
KMKerstin Mock
Kerstin Mock
VSVignesh Sundararajan
Vignesh Sundararajan
JPJessica Pfannstiel
Jessica Pfannstiel
MSMarc P. Stemmler
Marc P. Stemmler
Invasion and metastasis of carcinomas are often activated by induction of aberrant epithelial–mesenchymal transition (EMT). This is mainly driven by the transcription factor ZEB1, promoting tumor‐initiating capacity correlated with increased expression of the putative stem cell marker CD44. However, the direct link between ZEB1, CD44 and tumourigenesis is still enigmatic. Remarkably, EMT‐induced repression of ESRP1 controls alternative splicing of CD44, causing a shift in the expression from the variant CD44v to the standard CD44s isoform. We analyzed whether CD44 and ZEB1 regulate each other and show that ZEB1 controls CD44s splicing by repression of ESRP1 in breast and pancreatic cancer. Intriguingly, CD44s itself activates the expression of ZEB1, resulting in a self‐sustaining ZEB1 and CD44s expression. Activation of this novel CD44s‐ZEB1 regulatory loop has functional impact on tumor cells, as evident by increased tumor‐sphere initiation capacity, drug‐resistance and tumor recurrence. In summary, we identified a self‐enforcing feedback loop that employs CD44s to activate ZEB1 expression. This renders tumor cell stemness independent of external stimuli, as ZEB1 downregulates ESRP1, further promoting CD44s isoform synthesis.

31 October 2010 in Cancer Research
Verified
Journal Article
Closed access
PDF file
LHLionel W. Hebbard
Lionel W. Hebbard
Jochen MaurerJochen Maurer
Jochen Maurer
AMAmber Miller
Amber Miller
JLJacqueline Lesperance
Jacqueline Lesperance
JHJohn Hassell
John Hassell
ATAlexey V. Terskikh
Alexey V. Terskikh
Maternal embryonic leucine zipper kinase (MELK) is expressed in several developing tissues, in the adult germ line, and in adult neural progenitors. MELK expression is elevated in aggressive undifferentiated tumors, correlating with poor patient outcome in human breast cancer. To investigate the role of MELK in mammary tumorigenesis in vivo, we used a MELK-green fluorescent protein (GFP) reporter mouse, which allows prospective isolation of MELK-expressing cells based on GFP fluorescence. We found that in the normal mammary gland, cells expressing high levels of MELK were enriched in proliferating cells that express markers of mammary progenitors. The isolation of cells with high levels of MELK in mammary tumors from MMTV-Wnt1/MELK-GFP bitransgenic mice resulted in a significant enrichment of tumorsphere formation in culture and tumor initiation after transplantation into mammary fat pads of syngeneic mice. Furthermore, using lentiviral delivery of MELK-specific shRNA and limiting dilution cell transplantations, we showed that MELK function is required for mammary tumorigenesis in vivo. Our findings identify MELK as a potential target in breast tumor-initiating cells. Cancer Res; 70(21); 8863–73. ©2010 AACR.

31 October 2017 in Cancer Research
Verified
Journal Article
Open access
PDF file
EMEric Metzger
Eric Metzger
SSStella S. Stepputtis
Stella S. Stepputtis
JSJuliane Strietz
Juliane Strietz
BPBogdan-Tiberius Preca
Bogdan-Tiberius Preca
SUSylvia Urban
Sylvia Urban
RSRoland Schüle
Roland Schüle
Traditional treatments for breast cancer fail to address therapy-resistant cancer stem–like cells that have been characterized by changes in epigenetic regulators such as the lysine demethylase KDM4. Here, we describe an orally available, selective and potent KDM4 inhibitor (QC6352) with unique preclinical characteristics. To assess the antitumor properties of QC6352, we established a method to isolate and propagate breast cancer stem–like cells (BCSC) from individual triple-negative tumors resected from patients after neoadjuvant chemotherapy. Limiting-dilution orthotopic xenografts of these BCSCs regenerated original patient tumor histology and gene expression. QC6352 blocked BCSC proliferation, sphere formation, and xenograft tumor formation. QC6352 also abrogated expression of EGFR, which drives the growth of therapy-resistant triple-negative breast cancer cells. Our findings validate a unique BCSC culture system for drug screening and offer preclinical proof of concept for KDM4 inhibition as a new strategy to treat triple-negative breast cancer. Cancer Res; 77(21); 5900–12. ©2017 AACR.

9 April 2012 in Oncogene
Verified
Journal Article
Closed access
PDF file
JSJohannes H Schulte
Johannes H Schulte
SLS Lindner
S Lindner
ABA Bohrer
A Bohrer
Jochen MaurerJochen Maurer
Jochen Maurer
KPK De Preter
K De Preter
Alexander SchrammAlexander Schramm
Alexander Schramm

6 May 2019 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
EMEric Metzger
Eric Metzger
SWSheng Wang
Sheng Wang
SUSylvia Urban
Sylvia Urban
DWDominica Willmann
Dominica Willmann
ASAndreas Schmidt
Andreas Schmidt
RSRoland Schüle
Roland Schüle

25 July 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DMDanielle A Murphy
Danielle A Murphy
BDBegoña Diaz
Begoña Diaz
PBPaul A Bromann
Paul A Bromann
JTJeff H Tsai
Jeff H Tsai
YKYasuhiko Kawakami
Yasuhiko Kawakami
SCSara A Courtneidge
Sara A Courtneidge
In the adult organism, cell migration is required for physiological processes such as angiogenesis and immune surveillance, as well as pathological events such as tumor metastasis. The adaptor protein and Src substrate Tks5 is necessary for cancer cell migration through extracellular matrix in vitro and tumorigenicity in vivo. However, a role for Tks5 during embryonic development, where cell migration is essential, has not been examined. We used morpholinos to reduce Tks5 expression in zebrafish embryos, and observed developmental defects, most prominently in neural crest-derived tissues such as craniofacial structures and pigmentation. The Tks5 morphant phenotype was rescued by expression of mammalian Tks5, but not by a variant of Tks5 in which the Src phosphorylation sites have been mutated. We further evaluated the role of Tks5 in neural crest cells and neural crest-derived tissues and found that loss of Tks5 impaired their ventral migration. Inhibition of Src family kinases also led to abnormal ventral patterning of neural crest cells and their derivatives. We confirmed that these effects were likely to be cell autonomous by shRNA-mediated knockdown of Tks5 in a murine neural crest stem cell line. Tks5 was required for neural crest cell migration in vitro, and both Src and Tks5 were required for the formation of actin-rich structures with similarity to podosomes. Additionally, we observed that neural crest cells formed Src-Tks5-dependent cell protrusions in 3-D culture conditions and in vivo. These results reveal an important and novel role for the Src-Tks5 pathway in neural crest cell migration during embryonic development. Furthermore, our data suggests that this pathway regulates neural crest cell migration through the generation of actin-rich pro-migratory structures, implying that similar mechanisms are used to control cell migration during embryogenesis and cancer metastasis.